PALVELLA THERAPEUTICS, INC. 8-K

What Happened

• On May 15, 2026, Palvella Therapeutics, Inc. announced that new data from its Phase 2 TOIVA trial of QTORIN™ (rapamycin) in patients with cutaneous venous malformations were presented at the 83rd Annual Meeting of the Society for Investigative Dermatology. The company filed a press release about the presentation as Exhibit 99.1 to its Form 8-K.

Key Details

• Filing date: May 15, 2026 (Form 8-K, Item 8.01 Other Events).
• Drug and trial: QTORIN™ (rapamycin), Phase 2 TOIVA trial.
• Indication: patients with cutaneous venous malformations.
• Presentation: data were presented at the 83rd Annual Meeting of the Society for Investigative Dermatology; related press release filed as Exhibit 99.1.

Why It Matters

• The company publicly disclosed new Phase 2 clinical data at a major dermatology conference and filed the announcement with the SEC. For investors, conference presentations are formal milestones that make clinical results available to the scientific community and the market; they can provide updates on progress in development programs without being a regulatory filing of clinical outcomes or financial results. The 8-K is an official record of that disclosure.